USPTO serial 79202821
VECTURA
Reviewed by CopyMark Law Group
Reg. 5337619Status 709
- Filing date
- Status date
- Registration date
- Nov 21, 2017
- Examiner
- BLANDU, FLORENTINA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with VECTURA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Molly B. Markley
Molly B. Markley Young Basile Hanlon & MacFarlane P.C.3001 West Big Beaver RoadSuite 624Troy, MI 48084-3107Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and biological preparations for medical purpose, namely for the treatment of diseases or conditions of the respiratory system; pharmaceutical and biological preparations for medical purposes, namely the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical and biological preparations for medical purposes, namely for the alleviation or prevention of pain or inflammation; pharmaceutical and biological preparations for medical purposes, namely, powders for asthma inhalers; pharmaceutical and biological preparations for medical purposes, namely, powders for transdermal injection for the alleviation or prevention of pain, for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposes, namely for oral ingestion for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genitourinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposes, namely for topical administration for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purpose, namely, medicaments for inhalation therapy; pharmaceutical and biological preparations for medical purposes, namely, pulmonary delivery compositions for use in facilitating the inhalation of pharmaceuticals, namely, drug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals; pharmaceutical and biological preparations for medical purpose, namely medicaments for the treatment of erectile dysfunction, medicaments for the treatment of chronic obstructive pulmonary disease, medicaments for the treatment of premature ejaculation, medicaments for the treatment of cystic fibrosis, medicaments for the treatment of female sexual dysfunction, medicaments for the treatment of migraines, and medicaments for the treatment of asthma | SECTION 71 - CANCELLED | — |
| 010 | Drug delivery devices, namely, drug delivery systems; inhalers for medical use; metered dose inhalers for medical use; active dry powder inhalers for medical use; passive dry powder inhalers for medical use; nebulisers for respiration therapy; respirators for artificial respiration; parts and fittings for all the aforesaid goods | SECTION 71 - CANCELLED | — |
| 042 | Scientific research, development, design, analysis, testing and investigation relating to medical preparations and drug delivery devices; medical research; research relating to drug delivery devices; research relating to drug formulation; pharmaceutical development; preparation and formulation of pharmaceuticals; device and product testing namely device and product testing of drug delivery devices and medical preparations | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Vectura Limited
- Other trademarks owned by Vectura Limited
- Other trademarks owned by Vectura Limited
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named VECTURA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 17, 2025 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Apr 28, 2025 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Apr 28, 2025 | INPC | INVALIDATION PROCESSED | — |
| Feb 7, 2025 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jun 7, 2024 | C71T | CANCELLED SECTION 71 | — |
| Dec 22, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 21, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 8, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 27, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 3, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 2, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 21, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 21, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 5, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 5, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 16, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 23, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 21, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 20, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 20, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 2, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 16, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 16, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 16, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 15, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 11, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 10, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 9, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |